C2 PHARMA Receives CEP approval for Naphazoline Hydrochloride

Cork, Ireland — April 22, 2026 – C2 PHARMA, the global leader in ophthalmic active pharmaceutical ingredients (APIs), is pleased to announce that the European Directorate for the Quality of Medicines & HealthCare (EDQM) has granted a Certificate of Suitability (CEP) for Naphazoline Hydrochloride (see listing).

This approval further strengthens our ophthalmic portfolio and expands market access alongside our existing international registrations across key global markets. Regulatory authorities in numerous regions, including Asia Pacific and other CEP-recognizing territories, may rely on the CEP within their approval pathways, supporting broader availability of this important API worldwide.

Naphazoline Hydrochloride is a well-established sympathomimetic agent widely used in ophthalmic formulations for the temporary relief of ocular redness and irritation through vasoconstrictive action. The addition of this CEP reinforces our commitment to providing reliable and high-quality solutions for essential eye care therapies.

With this latest milestone, C2 PHARMA continues to expand one of the industry’s most comprehensive ophthalmic API portfolios, supporting partners worldwide with regulatory excellence, supply security, and specialized market expertise.